TAVR报销、新技术附加支付与手术量对栓塞保护装置使用的影响
本研究基于STS/ACC TVT注册数据库,分析2018年1月至2019年9月接受TAVR的84 353例患者,评估CMS报销费率与栓塞保护装置(EPD)使用的关系。结果显示EPD使用率仅7.1%,校正患者特征后较高报销与EPD使用相关,但进一步校正医院特征后关联消失;TAVR手术量而非报销或新技术附加支付是EPD使用的主要相关因素。
要点
- EPD在TAVR中的使用率较低,仅7.1%。
- 校正医院特征后,CMS报销与EPD使用无显著关联。
- TAVR手术量较高与EPD使用增加独立相关。
核心结论
- TAVR期间EPD使用仍不频繁,且与多种患者和医院特征相关。
- TAVR手术量而非CMS报销或新技术附加支付似乎是EPD使用的主要相关因素。
研究设计与样本
- 队列研究,使用STS/ACC TVT注册数据库识别2018年1月至2019年9月接受TAVR的患者。
- 共纳入511家机构的84 353例患者,中位年龄81.0岁,男性46 247例(54.8%)。
- 采用多变量逻辑回归模型,模型1校正患者特征,模型2额外校正医院年TAVR量和教学状态。
主要发现
- 6012例(7.1%)TAVR使用了EPD。
- CMS对TAVR的报销范围为28 062至111 280美元,中位数45 884美元(IQR 40 331-53 627)。
临床怎么用
- 临床中EPD使用决策需考虑患者特征(如既往卒中、女性、血液透析、休克)及医院手术量。
- 报销政策或新技术附加支付对EPD使用的影响可能有限,手术量是更重要的相关因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the setting of uncertain efficacy and additional, unreimbursed cost, use of an embolic protection device (EPD) during transcatheter aortic valve replacement (TAVR) has had variable uptake. The Centers for Medicare & Medicaid Services (CMS) instituted a new technology add-on payment to cover EPD use in October 2018. OBJECTIVE: To evaluate the association between CMS TAVR reimbursement rates and EPD use. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry to identify patients who underwent TAVR between January 2018 and September 2019. Analysis took place between July 2020 and February 2022. MAIN OUTCOMES AND MEASURES: The association between EPD use and CMS reimbursement was assessed using multivariable logistic regression models adjusted for patient characteristics (model 1) and patient/hospital (annualized TAVR volume and teaching status) characteristics (model 2). RESULTS: Among 511 institutions, CMS reimbursement for TAVR ranged from $28 062 to $111 280 with a median (IQR) of $45 884 ($40 331-$53 627). Among 84 353 patients (median [IQR] age, 81.0 [75.0-86.0] years; 46 247 male individuals [54.8%]; 3958 [4.7%] of Hispanic or Latino ethnicity; 78 170 White individuals [92.7%]) treated at the sites, 6012 (7.1%) underwent TAVR with EPD. Patient characteristics associated with EPD use included prior stroke (adjusted odds ratio [aOR], 1.13 [95% CI, 1.00-1.27]; P = .048), female sex (aOR, 0.85 [95% CI, 0.78-0.93]; P < .001), hemodialysis (aOR, 0.52 [95% CI, 0.40-0.68]; P < .001), and shock (aOR, 0.62 [95% CI, 0.41-0.94]; P = .03). Higher CMS reimbursement up to $50 000 per TAVR was associated with greater likelihood of EPD use in model 1 (per $1000; aOR, 1.08 [95% CI, 1.01-1.16]; P = .02). However, this association was no longer apparent after adjusting for site characteristics (model 2; aOR, 1.03 [95% CI, 0.96-1.11]; P = .38). Higher TAVR volume was associated with increased EPD use (per 25 TAVRs; aOR, 1.15 [95% CI, 1.09-1.21]; P < .001). There was no significant change in the odds of EPD uptake before vs after institution of the CMS new technology add-on payment across tertiles of CMS TAVR reimbursement (Wald χ2 = 3.59; P = .17). CONCLUSIONS AND RELEVANCE: EPD use during TAVR remains infrequent and is associated with multiple patient and site characteristics. While CMS reimbursement varies significantly across institutions, TAVR case volume, rather than CMS TAVR reimbursement or the CMS new technology add-on payment, appears to be the predominant factor associated with EPD use. Ongoing work is needed to understand the economic drivers that contribute to the association between procedural volume and EPD use.
引用
- Lowenstern A, Hung A, Manandhar P, et al. Association of Transcatheter Aortic Valve Replacement Reimbursement, New Technology Add-on Payment, and Procedure Volumes With Embolic Protection Device Use. JAMA Cardiol. 2022. PMID: 35976635. doi:10.1001/jamacardio.2022.2608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。